Sep 04, 2021
The development of phosphodiesterase type 5 (PDE5) inhibitors changed the treatment of erectile dysfunction (ED). The newest and most flexible PDE5 inhibitor in the therapeutic arsenal for the treatment of ED is tadalafil (vidalista 20mg). Its long half-life of 17.5 hours allows for a longer therapeutic window with on-demand dosing and effective steady-state plasma concentrations with once-daily dosing, allowing for a longer therapeutic window with on-demand dosing and effective steady-state plasma concentrations with once-daily dosing. Clinical trials have demonstrated its safety and effectiveness for all severities and etiologies of ED, including difficult-to-treat ED, using both dosage methods.
In 2003, two more PDE5 inhibitors were introduced to the market, broadening the ED therapy landscape and establishing PDE5 inhibitors as safe and efficient first-line therapies for ED. Increased potency and duration of effect were key considerations in the development of novel PDE5 inhibitors. The newest of the three PDE5 inhibitors, tadalafil (tadalista 20mg), works in a similar way to sildenafil and vardenafil (Levitra) in terms of mechanism of action, but has a longer duration of effect. Eli Lilly revealed the latest advancement in the treatment of ED in January 2008. If you want to know more please visit our safehealths site.